Sumitomo Pharma Co., Ltd. Environmental Analytics
Environmental and financial analysis dashboard for Sumitomo Pharma Co., Ltd.. Industry: MANUFACTURING
Company Overview for Sumitomo Pharma Co., Ltd.
Highlights
Showing data for FY2023
Operational Environmental Cost
$11m
Operational Environmental Cost Intensity
0.51%
Total Environmental Cost
$95m
Total Environmental Cost Intensity
4.56%
ΔOperational Environmental Cost (2020-2023)
$0.34m
Decoupling Rate (2020-2023)
-32%
Adjusted EBITDA
$-24m
Adjusted EBITDA Margin
-1.14%
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 18.31% | 41.47% | 3.03% | ||
| 0.08% | 0.10% | 0.15% | 0.31% | |
| 20.91% | 24.81% | -57.45% | ||
| 0.14% | 0.17% | 0.24% | 0.20% | |
| $10m | $12m | $16m | $11m | |
| 19.97% | 30.74% | -34.16% | ||
| 0.22% | 0.27% | 0.39% | 0.51% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| 6.36% | 4.02% | 2.61% | ||
| 1.59% | 1.71% | 1.96% | 4.04% | |
| 8.01% | 7.63% | -3.43% | ||
| 1.81% | 1.97% | 2.35% | 4.56% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
-1.14%
Adjusted EBIT Margin
-8.57%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$4,669m | $4,614m | $4,174m | $2,078m | |
| -1.18% | -9.53% | -50.21% | ||
N/A | $3,692m | $3,247m | $2,092m | |
| 0.00% | 80.02% | 77.79% | 100.63% | |
N/A | $922m | $927m | $-13m | |
| 0.00% | 19.98% | 22.21% | -0.63% | |
N/A | $719m | $641m | $-167m | |
| 0.00% | 15.59% | 15.36% | -8.06% | |
| ENVIRONMENTAL COST DATA | ||||
$10m | $12m | $16m | $11m | |
| 0.22% | 0.27% | 0.39% | 0.51% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
N/A | $910m | $911m | $-24m | |
| 0.00% | 19.72% | 21.82% | -1.14% | |
N/A | $707m | $625m | $-178m | |
| 0.00% | 15.32% | 14.97% | -8.57% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.31%
Scope 2 (% of Sales)
0.20%
Operational Environmental Cost Intensity
0.51%
Scope 3 (% of Sales)
4.04%
Total Environmental Cost Intensity
4.56%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Sumitomo Pharma Co., Ltd. | JP | $11m | 0.51% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023